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Abstract
Background: It is still unclear whether low high-density lipoprotein cholesterol (HDL-C) affects cardiovascular
outcomes after acute myocardial infarction (AMI), especially in patients with diabetes mellitus.
Methods: A total of 984 AMI patients with diabetes mellitus from the DIabetic Acute Myocardial InfarctiON Disease
(DIAMOND) Korean multicenter registry were divided into two groups based on HDL-C level on admission: normal
HDL-C group (HDL-C ≥ 40 mg/dL, n = 519) and low HDL-C group (HDL-C < 40 mg/dL, n = 465). The primary
endpoint was 2-year major adverse cardiovascular events (MACE), defined as a composite of cardiac death,
non-fatal myocardial infarction (MI), and target vessel revascularization (TVR).
Results: The median follow-up duration was 730 days. The 2-year MACE rates were significantly higher in the
low HDL-C group than in the normal HDL-C group (MACE, 7.44% vs. 3.49%, p = 0.006; cardiac death, 3.72% vs.
0.97%, p = 0.004; non-fatal MI, 1.75% vs. 1.55%, p = 0.806; TVR, 3.50% vs. 0.97%, p = 0.007). Kaplan-Meier analysis
revealed that the low HDL-C group had a significantly higher incidence of MACE compared to the normal
HDL-C group (log-rank p = 0.013). After adjusting for conventional risk factors, Cox proportional hazards analysis
suggested that low HDL-C was an independent risk predictor for MACE (hazard ratio [HR] 3.075, 95% confidence
interval [CI] 1.034-9.144, p = 0.043).
Conclusions: In patients with diabetes mellitus, low HDL-C remained an independent risk predictor for MACE after
adjusting for multiple risk factors during 2-year follow-up of AMI.
Trial registration: This study was the sub-analysis of the prospective multi-center registry of DIAMOND (Diabetic acute
myocardial infarction Disease) in Korea. This is the observational study supported by Bayer HealthCare, Korea. Study
number is 15614. First patient first visit was 02 April 2010 and last patient last visit was 09 December 2013.
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Background
Acute myocardial infarction (AMI) is a leading cause of
mortality in patients with diabetes mellitus. Recent data
revealed a 10–15% 1-year mortality rate after AMI in a
diabetic population [1]. Korean data also showed a
higher mortality rate after AMI in diabetic patients com-
pared to non-diabetic patients [2]. Preventive strategies
targeting platelet activity and lipid profiles in addition to
glycemic control and lifestyle modification are an essen-
tial part of management in these patients [3, 4].
Previous primary prevention trials revealed that low
high-density lipoprotein cholesterol (HDL-C) level is a
significant risk factor for cardiovascular events in the
general population [5, 6]. The Treating to New Targets
(TNT) study revealed that approximately 15% of patients
with diabetes mellitus have low HDL-C level [7]. In dia-
betes, insulin resistance increases triglyceride-enriched
HDL particles and causes more rapid clearance of HDL
particles [8]. Thus, low HDL-C is more common in dia-
betic patients. Moreover, previous epidemiologic studies
demonstrated a higher prevalence of low HDL-C in the
Asian population [9, 10]. The association between low
HDL-C and coronary heart disease seemed to be stronger
in the Asian population compared to non-Asians [11].
Recently, low HDL-C levels have been reportedly asso-
ciated with a higher rate of cardiovascular events in pa-
tients with stable coronary artery disease, percutaneous
coronary intervention, or even AMI [12–14]. However,
it is still controversial whether low HDL-C affects car-
diovascular outcomes after AMI. In addition, no studies
have evaluated AMI patients with diabetes mellitus. In
the present study, we have investigated the prevalence of




The DIAMOND (DIabetic Acute Myocardial infarctiON
Disease registry in Korea) study was a multicenter, pro-
spective observational study [15]. Briefly, between April
2010 and December 2013, 1,198 diabetic patients admit-
ted for AMI were enrolled at 22 institutions in South
Korea. The study participants were encouraged to follow
up at 1, 6, 12, and 24 months after discharge. The study
was approved by the institutional review board of each
institute and performed in accordance with the princi-
ples of the Declaration of Helsinki. Written informed
consent was obtained from all patients.
The present study was a retrospective analysis of pre-
viously collected data that were locked at December
2014. During the follow-up period, 6 patients withdrew
consent, 79 never followed up after discharge, and 129
had missing values for laboratory findings on admission.
Finally, 984 patients were analyzed.
Definitions
AMI was defined based on elevated cardiac troponin-I or
T level (exceeding upper limit of normal) or creatine
kinase-MB fraction (CK-MB) (exceeding three times
upper limit of normal), along with angiographic evidence.
Angiographic evidence for AMI included significant cor-
onary stenosis, i.e., more than 50% luminal stenosis, intra-
coronary filling defect or haziness suggesting coronary
thrombus/vulnerable plaque, or coronary artery vaso-
spasm confirmed by intracoronary acetylcholine or ergo-
novine provocation test. Diabetes mellitus was defined by
fasting plasma glucose level on two separate occasions ≥
126 mg/dL, a random plasma glucose level ≥ 200 mg/dL,
2-h plasma glucose post-75 g dextrose load on two separ-
ate occasions ≥ 200 mg/dL, or taking oral hypoglycemic
agents or using insulin. Dyslipidemia was defined as total
cholesterol level ≥ 240 mg/dL, low-density lipoprotein
cholesterol (LDL-C) level ≥ 130 mg/dL, HDL-C level <
40 mg/dL, triglyceride level ≥ 150 mg/dL, and/or treat-
ment with lipid lowering agents. Low HDL-C was defined
as < 40 mg/dL. Renal function was estimated with the
glomerular filtration rate (eGFR), which was calculated
with the Modification of Diet in Renal Disease (MDRD)
equation as following: eGFR (mL/min/1.73 m2) =
175 × (serum creatinine level)-1.154 × (age)-0.203 × (0.742 if
female) [16].
Endpoint
In the present analysis, major adverse cardiac events
(MACE) was defined as a composite of cardiac death,
non-fatal myocardial infarction (MI), and target vessel re-
vascularization (TVR). Revascularization other than TVR
(non-TVR) was also analyzed. Definite stent thrombosis
was assessed according to the Academic Research Consor-
tium definition.
Statistical analysis
Categorical variables were reported as count (percent-
age) and continuous variables as the mean ± standard
deviation. Comparisons between two groups were per-
formed using the independent Student’s t-test for con-
tinuous variables, and the χ2 test for categorical
variables. Kaplan–Meier survival curves with a log-rank
test and Cox proportional hazard model analyses were
performed to compare the long-term incidence of
MACE and cardiac death between the two groups. The
univariate and multivariate Cox proportional hazard re-
gression analyses were used to identify risk predictors
for MACE and cardiac death. The risk factors were
tested with the multivariate Cox proportional hazard re-
gression model by the backward selection method. The
candidate variables for the model included HDL-C level,
age, men, body mass index (BMI), current smoking, pre-
vious MI, ST-segment elevation myocardial infarction
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(STEMI) on admission, primary percutaneous coron-
ary intervention (PCI), hypertension, statin use, esti-
mated glomerular filtration rate (eGFR), hemoglobin A1c
(HbA1c) level, high-sensitivity C-reactive protein (hsCRP)
level, LDL-C level, left ventricular ejection fraction
(LVEF), multivessel disease, lesion type (B2/C), stent
diameter ≤ 2.75 mm, and stent length ≥ 28 mm. The selec-
tion significance level was 0.1. The results were expressed
as the hazard ratio (HR) with a 95% confidence interval
(CI) and p-value. All tests were two-tailed, and p-values
less than 0.05 were considered statistically significant. All
statistical analyses were performed using SAS (v. 9.3, SAS
Institute Inc., USA).
Results
Among a total of 984 diabetic patients who experienced
AMI, 465 patients (47.3%) were in the low HDL-C group.
Baseline clinical characteristics are summarized in Table 1.
The low HDL-C group had more men (p = 0.002). There
were fewer patients with newly diagnosed diabetes melli-
tus in the low HDL-C group (p = 0.034). Laboratory find-
ings showed lower total cholesterol and higher triglyceride
levels in the low HDL-C group (p < .001). Angiographic
findings showed no significant difference between the two
groups (Table 2).
In-hospital and 2-year clinical outcomes are shown
in Table 3. There were no significant differences in
in-hospital deaths and complications between the two
groups. The 2-year clinical outcomes were accessed in
the remaining 973 patients after excluding the pa-
tients with in-hospital death. Median follow-up period
was 730 days. During the follow-up period, the inci-
dence of MACE, cardiac death, and TVR was signifi-
cantly higher in the low HDL-C group (MACE, 7.44% vs.
3.49%, p = 0.006; cardiac death, 3.72% vs. 0.97%, p = 0.004;
non-fatal MI, 1.75% vs. 1.55%, p = 0.806; TVR, 3.50% vs.
0.97%, p = 0.007). Kaplan-Meier analysis revealed that the
low HDL-C group had a significantly higher incidence of






Age (years) 64.12 ± 9.91 65.10 ± 9.78 0.120
Male, n (%) 328 (70.54) 318 (61.27) 0.002
BMI (kg/m2) 24.23 ± 3.01 24.06 ± 3.02 0.301
Smoking, n (%) 164 (35.42) 166 (31.98) 0.255
Newly diagnosed DM, n (%) 30 (6.45) 53 (10.21) 0.034
Hypertension, n (%) 302 (65.09) 335 (64.92) 0.957
Dyslipidemia, n (%) 115 (24.78) 149 (28.76) 0.160
Previous MI, n (%) 28 (6.02) 33 (6.36) 0.827
On Admission
STEMI, n (%) 217 (46.67) 254 (48.94) 0.476
Primary PCI, n (%) 280 (60.22) 318 (61.27) 0.735
LVEF, n (%) 50.51 ± 12.31 51.00 ± 11.26 0.522
Total cholesterol (mg/dL) 162.92 ± 45.74 180.83 ± 44.34 <.001
Triglyceride (mg/dL) 151.59 ± 109.69 121.63 ± 83.35 <.001
LDL-C (mg/dL) 100.97 ± 34.76 105.63 ± 45.82 0.072
HDL-C (mg/dL) 32.70 ± 5.22 53.8 ± 26.83 <.001
Creatinine (mg/dL) 2.16 ± 16.55 1.69 ± 11.84 0.611
HbA1c (%) 7.83 ± 1.58 7.66 ± 1.49 0.111
hsCRP (mg/L) 6.00 ± 15.69 6.01 ± 24.07 0.993
Peak CK-MB (ng/mL) 75.71 ± 120.75 85.67 ± 122.03 0.202
Maximum Troponin-I
(ng/mL)
28.76 ± 55.53 29.71 ± 58.47 0.825
Medication at discharge
Aspirin, n (%) 449 (98.25) 510 (98.84) 0.442
Clopidogrel, n (%) 434 (94.97) 487 (94.38) 0.684
Cilostazol, n (%) 88 (19.26) 105 (20.35) 0.670
Beta blocker, n (%) 394 (85.65) 437 (84.36) 0.573
ACEI/ARB, n (%) 376 (81.74) 441 (85.14) 0.153
Statin, n (%) 381 (82.83) 452 (87.26) 0.052
Nitrate, n (%) 128 (27.83) 149 (28.76) 0.745
Insulin, n (%) 76 (16.52) 70 (13.51) 0.188
Data are presented as mean ± SD for continuous variables and numbers (%)
for categorical variables. BMI body mass index, DM diabetes mellitus, MI
myocardial infarction, STEMI ST-segment elevation MI, PCI percutaneous coron-
ary intervention, LVEF left ventricular ejection fraction, LDL-C low-density lipo-
protein cholesterol, HDL-C high-density lipoprotein cholesterol, HbA1c
hemoglobin A1c, hsCRP high-sensitivity C-reactive protein, CK-MB creatine
kinase-MB, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II
receptor blocker
Table 2 Angiographic and procedural characteristics
Low HDL Normal HDL p-value
Target vessel, n (%)
Left main 14 (3.01) 11 (2.12) 0.375
LAD 224 (48.17) 270 (52.02) 0.228
LCX 114 (24.52) 144 (27.75) 0.250
RCA 175 (37.63) 178 (34.30) 0.276
Multivessel disease, n (%) 284 (61.08) 302 (58.19) 0.357
Type B2/C lesion, n (%) 371 (84.9) 403 (80.76) 0.095
TIMI grade, n (%)
0 187 (42.79) 190 (38.08) 0.404
1 52 (11.90) 64 (12.83)
2 46 (10.53) 78 (15.63)
3 152 (34.78) 167 (33.47)
Drug-eluting stent, n (%) 398 (98.76) 445 (97.8) 0.294
Stent diameter (mm) 3.10 ± 0.45 3.13 ± 0.44 0.215
Stent length (mm) 25.44 ± 8.25 24.71 ± 9.12 0.272
Stent number 1.57 ± 0.89 1.55 ± 0.82 0.722
Data are presented as mean ± SD for continuous variables and numbers (%)
for categorical variables. LAD left anterior descending artery, LCX left
circumflex artery, RCA right coronary artery
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MACE and cardiac death compared to the normal HDL-
C group (MACE, log-rank p = 0.012; cardiac death, log-
rank p = 0.005; Fig. 1).
In multivariable Cox proportional hazard model ana-
lyses, HDL-C level, BMI, hypertension, and eGFR were
independent significant predictors for MACE [HDL-C,
HR (95% CI) 0.95 (0.905 - 0.999), p = 0. 047; BMI, HR
(95% CI) 0.84 (0.714 – 0.993), p = 0.041; hypertension,
HR (95% CI) 4.80 (1.052 – 21.927), p = 0.043; eGFR, HR
(95% CI) 0.981 (0.966 – 0.996), p = 0.016] after adjusting
for conventional risk factors (Table 4). LVEF remained
the only independent predictor for cardiac death [HR
(95% CI) 0.893 (0.828 – 0.964), p = 0.004].
Next, the unadjusted HRs for MACE were calcu-
lated in various subgroups based on age, sex, BMI,
smoking, HbA1c, LDL-C, creatinine, and LVEF (Fig. 2).
Interestingly, statistical significance was found in
patients with high BMI. There were no significant in-
teractions between HDL-C and MACE among the
other 7 subgroups.
Discussion
The main findings of the present study are as follows:
(1) 46.2% of diabetic patients presenting with AMI had a
low HDL-C level; (2) 2-year clinical outcomes including
MACE (mainly cardiac death and TVR) were poorer in
diabetic patients with a low HDL-C level after AMI
compared to those with a normal HDL-C level; (3) low
HDL-C level remained an important risk predictor for
MACE after adjusting for confounding clinical factors.
Previous community-based primary prevention studies
showed that low HDL-cholesterol level was strongly asso-
ciated with poor cardiovascular outcome in the general
population [17, 18]. Current guidelines strongly recom-
mend statin therapy for patients with overt atherosclerotic
vascular diseases and diabetes mellitus [19, 20]. A previous
study demonstrated that statin therapy increased HDL-C
level by approximately 7.5%, and was associated with
coronary atherosclerotic regression [21]. However,
more than 40% of statin-treated patients have a persist-
ently low HDL-C level [22, 23]. Several studies also
suggested low HDL-C as an independent risk predictor,
even in patients with overt atherosclerotic vascular dis-
eases on statin therapy. Seo et al. reported that a low
HDL-C level on statin therapy was associated with poor
clinical outcome after PCI [12]. Ogital et al. also showed
that low HDL-C was a risk factor in diabetic patients with
stable coronary artery disease [13]. Recently, Lee et al.
showed similar results in patients with AMI [14]. The
present study showed a higher MACE rate in diabetic
AMI patients with low HDL-C level compared to those
with a normal HDL-C level.
On the other hand, several studies have questioned the
impact of HDL-C on cardiovascular prognosis. Izuhara et
Table 3 In-hospital and 2-year clinical outcomes after acute
myocardial infarction
Low HDL Normal HDL p-value
In-hospital
Death 8 (1.72) 3 (0.58) 0.089
Cardiogenic shock 10 (2.15) 6 (1.16) 0.218
Acute renal failure 5 (1.08) 2 (0.39) 0.199
Major bleeding 4 (0.86) 6 (1.16) 0.644
During follow-up period
MACE 34 (7.44) 18 (3.49) 0.006
Cardiac death 17 (3.72) 5 (0.97) 0.004
Non-fatal MI 8 (1.75) 8 (1.55) 0.806
TVR 16 (3.50) 5 (0.97) 0.007
Non-TVR 11 (2.41) 12 (2.33) 0.934
Stent thrombosis, definite 3 (0.65) 1 (0.19) 0.266
Data are presented as numbers (%) for categorical variables. MACE major
adverse cardiac event, MI myocardial infarction, TVR target
vessel revascularization
Fig. 1 Kaplan-Meier analysis of low HDL-C and normal HDL-C groups. a cumulative MACE-free survival. b cumulative cardiac death-free survival.
HR, hazard ratio; 95% CI, 95% confidence interval; Ref, reference
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al. showed that the statistical significance of low HDL-C
in poor clinical outcomes disappeared after adjusting for
confounding factors in patients who underwent PCI [23].
Angeloni et al. showed similar 3-year MACE rates in low
and high HDL-C groups, even in patients who underwent
coronary artery bypass grafting [24]. Ji et al. also showed
no significant difference in 1-year MACE rates between
the two groups in AMI patients [25].
The discrepancy among studies might be explained by
several factors. First, the studies were performed in dif-
ferent clinical settings and had different demographic
and risk profiles. The clinical situations could have af-
fected the anti-atherogenic and anti-inflammatory func-
tion of HDL-C. Recently, many studies have focused on
the function of HDL-C rather than the level. HDL-C
plays an important role in atherogenesis through reverse
cholesterol transport. Removing cholesterol from macro-
phages (called “macrophage cholesterol efflux”) is signifi-
cantly associated with cardiovascular events [26, 27].
Cholesterol efflux capacity and the NO-producing effect
of HDL-C were also decreased in patients with acute
coronary syndrome [28, 29]. Dysfunction of HDL-C was
also reported in diabetic patients [30]. These findings
suggested that HDL-C dysfunction might mask the clin-
ical significance of serum HDL-C level for cardiovascular
prognosis depending on the clinical situation. In other
words, the quality of HDL-C might be more significant
than the quantity in selected populations. Second, the
cut-off value of HDL-C could affect the results of clin-
ical studies. Interestingly, the studies using the cut-off
Table 4 Univariate and multivariate analysis for risk factors to predict MACE and cardiac death
MACE Cardiac death
Risk Factor β HR (95% CI) p-value β HR (95% CI) p-value
Univariate analysis
Age 0.04 1.04 (1.007 – 1.066) 0.014 0.10 1.10 (1.048 – 1.158) <0.001
Male −0.10 0.90 (0.513 – 1.588) 0.723 −0.33 0.72 (0.306 – 1.677) 0.443
BMI −0.02 0.98 (0.895 – 1.073) 0.666 −0.20 0.82 (0.703 – 0.947) 0.008
Current Smoking −0.41 0.66 (0.354 – 1.243) 0.200 −0.56 0.57 (0.210 – 1.543) 0.268
Previous MI −0.55 0.58 (0.327 – 1.026) 0.061 −0.92 0.40 (0.157 – 1.023) 0.056
Hypertension 1.67 5.31 (2.113 – 13.363) <0.001 1.26 3.51 (1.038 – 11.858) 0.043
HDL-C −0.05 0.95 (0.928 – 0.981) 0.001 −0.08 0.92 (0.879 – 0.963) <0.001
LDL-C −0.01 0.99 (0.986 – 1.001) 0.098 −0.01 1.00 (0.983 – 1.007) 0.395
eGFR −0.02 0.99 (0.977 – 0.994) 0.001 −0.03 0.973 (0.960 – 0.986) <0.001
Hba1c 0.02 1.02 (0.852 – 1.231) 0.802 0.13 1.14 (0.880 – 1.482) 0.319
hsCRP 0.002 1.00 (0.988 – 1.017) 0.786 0.003 1.00 (0.985 – 1.022) 0.739
STEMI at admission −0.55 0.58 (0.327 – 1.026) 0.061 −0.92 0.40 (0.157 – 1.023) 0.056
Primary PCI −0.38 0.685 (0.397 – 1.183) 0.175 −1.27 0.28 (0.115 – 0.693) 0.006
MVD 0.13 1.14 (0.649 – 2.008) 0.647 −0.22 0.80 (0.347 – 1.859) 0.608
Lesion type (B2/C) 0.05 1.05 (0.466 – 2.346) 0.914 −0.60 0.55 (0.175 – 1.727) 0.306
Stent diameter ≤2.75 mm 0.02 1.02 (0.490 – 2.124) 0.958 −1.27 0.28 (0.035 - 2.211) 0.227
Stent length ≥28 mm 0.49 1.64 (0.842 – 3.174) 0.146 0.41 1.51 (0.437 – 5.209) 0.516
LVEF −0.04 0.96 (0.941 – 0.986) 0.002 −0.10 0.904 (0.870 – 0.939) <0.001
Statin at discharge −0.35 0.71 (0.354 – 1.407) 0.322 −0.83 0.44 (0.170 – 1.113) 0.083
Multivariate analysis
HDL-C −0.05 0.95 (0.905 - 0.999) 0.047 - - -
Age −0.05 0.96 (0.906 – 1.006) 0.085 - - -
BMI −0.17 0.84 (0.714 – 0.993) 0.041 −0.31 0.73 (0.537 – 1.002) 0.051
Hypertension 1.57 4.80 (1.052 – 21.927) 0.043 - - -
eGFR −0.02 0.981 (0.966 – 0.996) 0.016 −0.02 0.98 (0.954-1.004) 0.093
Stent diameter ≤2.75 mm - - - −1.81 0.16 (0.017 – 1.587) 0.119
LVEF - - - −0.11 0.893 (0.828 – 0.964) 0.004
MACE major adverse cardiovascular events, HR hazard ratio, 95% CI 95% confidence interval, BMI body mass index, MI myocardial infarction, LDL-C low-density lipo-
protein cholesterol, eGFR estimated glomerular filtration rate, hsCRP high-sensitivity C-reactive protein, STEMI ST-segment elevation myocardial infarction, PCI per-
cutaneous coronary intervention, MVD multi-vessel disease, LVEF left ventricular ejection fraction, n.d. not determined
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value of 40 mg/dL suggested that low HDL-C was an in-
dependent risk predictor [12–14]. Other studies using
different cut-off values for men and women (40 mg/dL
for men and 50 mg/dL for women) failed to show the
significance of low HDL-C [23–25]. More importantly, 2
studies from the same AMI registry showed different re-
sults. One adopted the cut-off value of 40 mg/dL for
both men and women [14], and the other study used dif-
ferent cut-off values for men and women (40 mg/dL for
men and 50 mg/dL for women) [25]. In the present
study, receiver operating characteristic (ROC) curves of
HDL-C for cardiac death showed that the area under the
curve (AUC) for men was 0.722 and 0.753 for women
(Additional file 1: Figure S1); optimal cut-off points with
the Youden index were 38 mg/dL for men and 35 mg/dL
for women. ROC curves of HDL-C for MACE showed
that the AUC for men was 0.634 and 0.660 for women;
optimal cut-off points with the Youden index were
38 mg/dL for men and 40 mg/dL for women. Thus, we
used the same cut-off value of 40 mg/dL for both men
and women. Moreover, 2015 Korean guidelines for the
management of dyslipidemia adopted a criterion of
below 40 mg/dL as low HDL-C for both men and
women [31].
A genetic mechanism reportedly links low HDL-C and
inflammatory states [32]. Hoven et al. also showed a
clinical relationship between low HDL-C level and its in-
flammatory and oxidative phenotype [33]. Moreover,
there is much experimental evidence for the beneficial
effects of HDL-C [34]. Although previous clinical trials
aimed at raising HDL-C failed to show promising results
[35–38], new HDL-C-based strategies designed to im-
prove HDL-C functionality instead of increasing the
HDL-C level have been under development [39, 40].
There are several limitations. First, the study subjects
were divided into only 2 groups. We did not address the
impact of the other ranges of HDL-C level (e.g., HDL-
C > 70 mg/dL or < 20 mg/dL) due to the limited patient
numbers. Thus, the possible protective role of high
HDL-C level or its dose–response relationship could not
be investigated. Second, the current guidelines recom-
mend statin therapy for diabetic patients regardless of
their lipid profile [31, 41]. Detailed information (name
and dose) on statins and other medications affecting
HDL-C levels were not assessed. However, the effect of
statins on HDL-C has been known to be relatively small.
Moreover, our data highlighted the clinical limitations of
current statin usage and proposed HDL-C as a thera-
peutic target despite the failures of previous trials. Third,
the follow-up rate of HDL-C was only 62.0% in the
present study. Data on HDL-C levels before admission
were not obtained. Thus, we cannot analyze the dynam-
ics of HDL-C. Fourth, serum uric acid level was not in-
cluded and adjusted for a potential confounding factor.
Although the relationship between serum uric acid level
and the prognosis of acute myocardial infarction has
Fig. 2 Comparative unadjusted hazard ratios of MACE for subgroups. MACE, major adverse cardiovascular events; 95% CI, 95% confidence
interval; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction
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been still controversial, serum uric acid level is a well-
known surrogate marker for inflammation and athero-
sclerosis [42]. Unfortunately, serum uric acid level was
not available in our registry. Additional data including
serum uric acid level and other inflammatory biomarkers
could be more informative to understanding the clinical
impact of HDL-C.
Conclusions
The 2-year incidence of MACE, cardiac death, and TVR
was significantly higher in diabetic patients with a low
HDL-C level compared to those with a normal HDL-C
level after AMI. Low HDL-C level remained an inde-
pendent risk predictor for both MACE and cardiac death
after adjusting for multiple risk factors.
Additional file
Additional file 1: Figure S1. Receiver operating characteristic (ROC)
curves of HDL-C for MACE and cardiac death. (DOCX 346 kb)
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